期刊文献+

阿司匹林加氯吡格雷强化抗血小板治疗急性冠脉综合征的临床观察 被引量:1

下载PDF
导出
摘要 目的探讨阿司匹林联合氯吡格雷强化抗血小板治疗急性冠脉综合征的有效性和安全性。方法选择2007年3月-2008年5月符合急性冠脉综合征诊断标准患者186例为研究对象,随机分为两组,阿司匹林治疗组93例,给予低分子肝素、β-受体阻滞剂、他汀类调脂药、血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体拮抗剂、钙拮抗剂、硝酸酯类等常规药物治疗;阿司匹林联合氯吡格雷治疗组93例,在常规治疗基础上加用氯吡格雷75mg/d,治疗4周,比较两组主要心血管不良事件和出血发生率。结果联用氯吡格雷组主要心血管不良事件(包括心原性死亡、再发或新发急性心肌梗死、反复心绞痛发作)发生率明显下降(P〈0.05),出血发生率与单用阿司匹林比较差异无统计学意义。结论急性冠脉综合征患者应用阿司匹林加氯吡格雷强化抗血小板治疗是有效和安全的。
出处 《中国血液流变学杂志》 CAS 2009年第1期48-49,共2页 Chinese Journal of Hemorheology
  • 相关文献

参考文献4

二级参考文献33

  • 1Fragnfin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet, 1996,347:561-568.
  • 2Klein W, Buchwald A, Hillis SE, et al. Comparison of low- molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC) . Circulation, 1997,96:61-68.
  • 3Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfraetionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction : FRAX. I.S. ( FRAxiparine in Ischaemic Syndrome). Eur Heart J, 1999,20 : 1553-1562.
  • 4Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low- molecular-weight heparin with unfract/onated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med, 1997,337:447-452.
  • 5Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/ non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) llB trial. Circulation, 1999,100: 1593-1601.
  • 6FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC Ⅱ prospective randomised multicentre study. Lancet, 1999,354:708- 715.
  • 7Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. Eur Heart J, 2003,24:897-908.
  • 8Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med ,2006 ,354 :1477-1488.
  • 9Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med, 2006, 354 : 1464-1476.
  • 10Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction : the OASIS-6 randomized trial. JAMA, 2006,295:1519-1530.

共引文献211

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部